Matt joined Compass Carter Osborne in 2023 bringing more than seven years of experience partnering with public and investor backed pharmaceutical, biotech, medtech and pharmaceutical services firms across EMEA and North America with a focus on Board, C-suite and senior leadership mandates. He has a particular interest in the Cell & Gene Therapy ecosystem.
His experience covers CEO and General Management mandates as well as functional leadership roles in Business Development & Licensing, Commercial, Clinical Operations, Technical Operations and Drug Discovery functions.
CEO | NK:IO | VC backed
Head of Business Development, Biologics | Curia | International Investors
VP Managing Director | Eurofins Gold Standard Diagnostics | Public